Canaccord Genuity Group Reaffirms Buy Rating for KORU Medical Systems (NASDAQ:KRMD)

KORU Medical Systems (NASDAQ:KRMD)‘s stock had its “buy” rating reiterated by research analysts at Canaccord Genuity Group in a note issued to investors on Friday,Benzinga reports. They presently have a $6.00 target price on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 39.70% from the stock’s previous close.

Several other analysts have also issued reports on KRMD. Wall Street Zen upgraded KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 12th. B. Riley Financial lifted their price objective on KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday. Craig Hallum restated a “buy” rating and issued a $7.00 price objective on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Finally, Lake Street Capital lifted their target price on shares of KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $6.50.

KORU Medical Systems Stock Performance

Shares of KORU Medical Systems stock traded down $0.02 on Friday, reaching $4.30. 292,414 shares of the company traded hands, compared to its average volume of 198,815. The company has a 50 day moving average of $5.13 and a 200 day moving average of $4.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.48 and a quick ratio of 1.92. KORU Medical Systems has a 52 week low of $1.86 and a 52 week high of $6.61. The firm has a market capitalization of $198.94 million, a PE ratio of -53.69 and a beta of 0.47.

KORU Medical Systems (NASDAQ:KRMD) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. KORU Medical Systems had a negative net margin of 9.49% and a negative return on equity of 22.43%. The company had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $10.90 million. Equities analysts forecast that KORU Medical Systems will post -0.13 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of KORU Medical Systems during the second quarter valued at about $30,000. BNP Paribas Financial Markets grew its stake in KORU Medical Systems by 52.1% during the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after acquiring an additional 3,478 shares in the last quarter. Lazard Asset Management LLC bought a new stake in KORU Medical Systems during the 2nd quarter worth approximately $59,000. Acadian Asset Management LLC bought a new stake in KORU Medical Systems during the 1st quarter worth approximately $63,000. Finally, Intech Investment Management LLC purchased a new stake in KORU Medical Systems in the 2nd quarter worth approximately $73,000. Institutional investors own 58.60% of the company’s stock.

KORU Medical Systems News Roundup

Here are the key news stories impacting KORU Medical Systems this week:

• Positive Sentiment: KORU reported fourth‑quarter revenue growth and a small EPS beat (Q4 EPS -$0.01 vs. consensus -$0.02) and matched revenue expectations, showing improvement vs. a year ago. This supports the stock’s upside today. KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: The company announced ~20% revenue growth for Q4 and full‑year 2025, delivered positive adjusted EBITDA, and initiated FY‑2026 guidance (revenue range roughly $47.5M–$50.0M), giving investors a clearer near‑term outlook. KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
• Positive Sentiment: KORU received EU MDR certification for its Freedom60® infusion pump with prefilled syringe compatibility — a regulatory clearance that can support European commercialization and recurring revenue potential. KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
• Neutral Sentiment: KORU held its Q4 earnings call; the transcript provides details on growth drivers, product adoption, and margin trends for investors who want management color. KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: The company announced a CEO transition: longtime CEO Linda Tharby will retire effective June 30, 2026 and Adam Kalberma has been appointed. Leadership change adds execution risk uncertainty but also a planned succession. KORU Medical Systems Announces CEO Transition
• Negative Sentiment: Despite progress, KORU remains GAAP unprofitable (negative net margin ~9.5% and negative ROE) and posted a small per‑share loss; continued losses and modest scale could limit valuation expansion until profitability sustainably improves. Earnings release and financial details

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.